EU/3/14/1295 - orphan designation for treatment of plasma cell myeloma

Marizomib

Overview

On 29 July 2014, orphan designation (EU/3/14/1295) was granted by the European Commission to Richardson Associates Regulatory Affairs Ltd, United Kingdom, for marizomib for the treatment of plasma cell myeloma.

The sponsorship was transferred to Celgene Europe Limited, United Kingdom, in February 2018.

The sponsorship was transferred to Celgene Europe B.V., The Netherlands, in July 2018.

What is plasma cell myeloma?

Plasma cell myeloma (also called multiple myeloma) is a cancer of a type of white blood cell called plasma cells. Plasma cells originate from the bone marrow, the spongy tissue inside the large bones in the body. In plasma cell myeloma the division of plasma cells becomes out of control, resulting in abnormal, immature plasma cells multiplying and filling up the bone marrow. This interferes with the production of normal white blood cells, red blood cells and platelets (components that help the blood to clot), leading to complications such as anaemia (low red blood cell counts), bone pain and fractures, raised blood calcium levels and kidney disease.

Plasma cell myeloma is a debilitating and life-threatening disease particularly because it disrupts the normal functioning of the bone marrow, damages the bones and causes kidney failure.

What is the estimated number of patients affected by the condition?

At the time of designation, plasma cell myeloma affected approximately 3.6 in 10,000 people in the European Union (EU). This was equivalent to a total of around 185,000 people*, and is below the ceiling for orphan designation, which is 5 people in 10,000. This isbased on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).

---

*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 28), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 512,900,000 (Eurostat 2014).

What treatments are available?

At the time of designation, several medicines were already authorised for plasma cell myeloma in the EU. The main treatment for plasma cell myeloma was chemotherapy (medicines to treat cancer) usually combined with steroids to reduce the activity of the immune system, the body's natural defences. Where chemotherapy did not work, some patients received an allogeneic stem-cell transplant (a complex procedure where the patient receives stem cells from a matched donor to help restore the bone marrow). Radiotherapy (using radiation to kill cancer cells) was used to treat pain due to bone damage and prevent further damage. Interferon alfa was sometimes used in combination with chemotherapy.

The sponsor has provided sufficient information to show that marizomib might be of significant benefit for patients with plasma cell myeloma because preliminary study results suggested that it could produce improvements in patients whose disease had come back or got worse after standard treatment. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

Marizomib blocks several actions of the proteasome, which is a system within the cells that breaks down proteins when they are no longer needed. It is thought that cancer cells, such as the abnormal plasma cells in myeloma, have an increased need to produce and break down proteins due to the fact that they are multiplying rapidly. In plasma myeloma cells, marizomib is expected to stop proteins from being broken down properly, leading eventually to the death of the cancer cells and so slowing down the growth of the cancer.

What is the stage of development of this medicine?

The effects of marizomib have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with marizomib in patients with plasma cell myeloma were ongoing.

At the time of submission, marizomib was not authorised anywhere in the EU for plasma cell myeloma. Orphan designation of marizomib had been granted in the United States for treatment of multiple myeloma (plasma cell myeloma).

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 12 June 2014 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:

• the seriousness of the condition;
• the existence of alternative methods of diagnosis, prevention or treatment;
• either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

EU/3/14/1295: Public summary of opinion on orphan designation: Marizomib for the treatment of plasma cell myeloma

AdoptedReference Number: EMA/COMP/360650/2014 Rev. 1

Key facts

• Active substance:
  Marizomib
• Intended use:
  Treatment of plasma cell myeloma
• Orphan designation status:
  Positive
• EU designation number:
  EU/3/14/1295
• Date of designation:
  29/07/2014
• Sponsor:

  Celgene Europe B.V.; Winthontlaan 6 N; 3526 KV Utrecht; The Netherlands; Tel. [phone]; E-mail: [e-mail]

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.